Completed PHASE2 INTERVENTIONAL 1-arm NCT03438396

A Trial of Tisotumab Vedotin in Cervical Cancer

A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer

Sponsor: Belgian Gynaecological Oncology Group

Conditions Cervical Cancer

Interventions tisotumab vedotin

Updated 20 times since 2018 Last updated: Jul 11, 2023 Started: Jun 12, 2018 Primary completion: Feb 6, 2020 Completion: Aug 2, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cervical Cancer and is currently completed. Belgian Gynaecological Oncology Group leads this study, which shows 20 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

20 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Aug 2023 — Jul 2024 [monthly]

Completed PHASE2
Sep 2022 — Aug 2023 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed

▶ Show 15 earlier versions

Dec 2021 — Sep 2022 [monthly]

Active Not Recruiting PHASE2
Apr 2021 — Dec 2021 [monthly]

Active Not Recruiting PHASE2
Mar 2021 — Apr 2021 [monthly]

Active Not Recruiting PHASE2
Jan 2021 — Mar 2021 [monthly]

Active Not Recruiting PHASE2
Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2
Nov 2020 — Dec 2020 [monthly]

Active Not Recruiting PHASE2
Aug 2020 — Nov 2020 [monthly]

Active Not Recruiting PHASE2
Jun 2019 — Aug 2020 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2019 — Jun 2019 [monthly]

Recruiting PHASE2
Dec 2018 — Feb 2019 [monthly]

Recruiting PHASE2
Oct 2018 — Dec 2018 [monthly]

Recruiting PHASE2
Aug 2018 — Oct 2018 [monthly]

Recruiting PHASE2
Jul 2018 — Aug 2018 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2018 — Jul 2018 [monthly]

Not Yet Recruiting PHASE2
Mar 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Belgian Gynaecological Oncology Group
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Genmab
Gynecologic Oncology Group
Seagen Inc.

Data source: Seagen Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aalborg, Denmark , Albuquerque, United States , Atlanta, United States , Barcelona, Spain , Birmingham, United States , Bologna, Italy , Brno, Czechia , Bruges, Belgium , Brussels, Belgium and 37 more locations